Stefanie Cavanaugh Net Worth

The estimated Net Worth of Stefanie L. Cavanaugh is at least $659 Thousand dollars as of 20 June 2018. Ms. Cavanaugh owns over 4,545 units of Apollo Endosurgery Inc stock worth over $195,690 and over the last 8 years she sold APEN stock worth over $0. In addition, she makes $463,415 as Chief Financial Officer and Secretary at Apollo Endosurgery Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Cavanaugh APEN stock SEC Form 4 insiders trading

Stefanie has made over 2 trades of the Apollo Endosurgery Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she bought 4,545 units of APEN stock worth $24,998 on 20 June 2018.

The largest trade she's ever made was buying 4,545 units of Apollo Endosurgery Inc stock on 20 June 2018 worth over $24,998. On average, Stefanie trades about 758 units every 28 days since 2016. As of 20 June 2018 she still owns at least 19,569 units of Apollo Endosurgery Inc stock.

You can see the complete history of Ms. Cavanaugh stock trades at the bottom of the page.

Stefanie Cavanaugh biography

Stefanie L. Cavanaugh CPA serves as Chief Financial Officer, Secretary of the Company. Since March 2015, Ms. Cavanaugh has served as Chief Financial Officer of Apollo. From 2014 to 2015, Ms. Cavanaugh provided advisory services to several healthcare companies. From 2010 to 2014, Ms. Cavanaugh served as Senior Vice President of Finance at Harden Healthcare, LLC, a provider of healthcare services for the long-term care industry, until its sale to Gentiva Health Services, Inc. Ms. Cavanaugh holds a B.B.A. in Accounting and Finance from the University of Texas at Austin and is a Certified Public Accountant.

What is the salary of Stefanie Cavanaugh?

As the Chief Financial Officer and Secretary of Apollo Endosurgery Inc, the total compensation of Stefanie Cavanaugh at Apollo Endosurgery Inc is $463,415. There are 4 executives at Apollo Endosurgery Inc getting paid more, with Christopher Gostout having the highest compensation of $1,156,870.

How old is Stefanie Cavanaugh?

Stefanie Cavanaugh is 55, she's been the Chief Financial Officer and Secretary of Apollo Endosurgery Inc since 2015. There are 12 older and 6 younger executives at Apollo Endosurgery Inc. The oldest executive at Apollo Endosurgery Inc is Dr. Christopher J. Gostout, 70, who is the Co-Founder & Chief Medical Officer.

What's Stefanie Cavanaugh's mailing address?

Stefanie's mailing address filed with the SEC is 1120 S Capital of Texas Hwy #300, Austin, TX 78746, USA.

Insiders trading at Apollo Endosurgery Inc

Over the last 12 years, insiders at Apollo Endosurgery Inc have traded over $3,882,241 worth of Apollo Endosurgery Inc stock and bought 10,717,094 units worth $45,588,363 . The most active insiders traders include Holdings A/S Novo, Neil Gagnon, and R Kent Jr Mc Gaughy. On average, Apollo Endosurgery Inc executives and independent directors trade stock every 41 days with the average trade being worth of $2,726,880. The most recent stock trade was executed by Jeffrey G. Black on 25 February 2022, trading 40,000 units of APEN stock currently worth $229,200.

What does Apollo Endosurgery Inc do?

Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.

Complete history of Ms. Cavanaugh stock trades at Apollo Endosurgery Inc

Apollo Endosurgery Inc executives and stock owners

Apollo Endosurgery Inc executives and other stock owners filed with the SEC include:

• Christopher Gostout,
  Chief Medical Officer
• Todd Newton,
  Chief Executive Officer, Director
• John J. Molesphini,
  Exec. VP of Operations
• Bret Schwartzhoff,
  Vice President - North America Sales and Global Marketing
• Stefanie Cavanaugh,
  Chief Financial Officer, Secretary
• K. Todd Newton,
  Consultant
• Bret Schwartzhoff,
  VP, US Sales & Global Marketing
• Julie Shimer,
  Independent Director
• Bruce Robertson,
  Independent Director
• David Pacitti,
  Independent Director
• R. Kent McGaughy,
  Independent Director
• William McClellan,
  Independent Director
• John Barr,
  Independent Director
• Rick Anderson,
  Independent Director
• John Molesphini,
  Executive Vice President - Operations
• Dr. Christopher J. Gostout M.D.,
  Co-Founder & Chief Medical Officer
• Jeffrey G. Black,
  Chief Financial Officer
• Dr. Pankaj Jay Pasricha FACP, M.D., MBBS,
  Co-Founder
• Dr. Christopher J. Gostout,
  Co-Founder & Chief Medical Officer
• Sydney Chung M.D.,
  Co-Founder and Innovation Partner
• Dr. Peter Benjamin Cotton M.D.,
  Co-Founder and Innovation Partner
• Dr. Robert Hawes M.D.,
  Co-Founder and Innovation Partner
• Anthony Kalloo M.D.,
  Co-Founder and Innovation Partner
• Dr. Sergey Kantsevoy M.D.,
  Co-Founder and Innovation Partner
• Charles S. McKhann,
  CEO, Pres & Director
• Sciences Ii L Pptv Iv, L.P....,
  
• Ventures Llc Remeditex,
  10% owner
• Richard J Meelia,
  Director
• Dennis L. Mc Williams,
  President, CCO
• Ventures Endosurgery, Llc...,
  10% owner
• Holdings A/S Novo,
  10% owner
• John W Creecy,
  Director
• Charles Tribie,
  Executive V.P. of Operations
• Chas Mc Khann,
  President and CEO
• Sciences Ii L Pptv Iv, L.P....,
  
• Sciences Ii L Pptv Iv, L.P....,
  
• Capital, L.P. Stonepine,
  10% owner
• Sciences Ii L Pptv Special ...,
  
• Inc Cpmg,
  
• James W Jr Traweek,
  
• Neil Gagnon,
  10% owner
• Sciences Ii L Pptv Iv, L.P....,
  
• Inc Desai Antal Rohit Cpmg,
  
• Matthew S Crawford,
  10% owner
• Jeffrey G. Black,
  Chief Financial Officer
• Mike Gutteridge,
  VP, Int'l Sales and Marketing
• Sharon O'keefe,
  Director
• Jeannette Bankes,
  Director